sPARK.
2024

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K, Jang GH, … Park W, …

Cancer Cell 42(9), 1614–1629

sPARK LabWungki ParkEileen O'Reilly
KRASPDACGenomics
74Citations
2024Year

Research Programs

ProgramKRAS-driven Vulnerabilities

Related by topic

Publication · KRAS, Genomics, PDACClinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survivalPublication · Genomics, PDACAlterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinomaResearch Program · KRAS, GenomicsBiliary Tract CancerProject / Trial · KRAS, PDACDaraxonrasib (RMC-6236)Publication · KRAS, PDACDaraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic CancerPublication · Genomics, PDACEarly-onset pancreas cancer: clinical descriptors, genomics, and outcomes

Local graph

Tap a node to select · use + / − to zoom · enable Move graph to drag

Browse nodes (6)
Open full graph →